Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib sensitization of recurrent glioblastoma to temozolomide
2017-001690-16Phase 2Active
- Sponsor
- Helse Bergen
- Start
- Jan 2018
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and temozolomide in glioblastoma (GBM), sponsored by Helse Bergen. Primary endpoints: Overall survival at 1 year and Safety and tolerability (Phase 1B). Started Jan 2018; status: active.
02
Drugs
bortezomibtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2017-001690-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001690-16.